Jon Oliner

University of Wisconsin–Madison — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

7h-index2.7kcitations19works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Research and Treatments(7), Immunotherapy and Immune Responses(6), Cancer Immunotherapy and Biomarkers(5), Angiogenesis and VEGF in Cancer(3), Cancer-related Molecular Pathways(2)

Publications19 total

A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity
Journal of Translational Medicine·2026Open Access
Additional file 1 of A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity
Figshare·2026Open Access
Additional file 2 of A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity
Figshare·2026Open Access
Additional file 1 of A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity
Figshare·2026Open Access
Additional file 2 of A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity
Figshare·2026Open Access
A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity
Figshare·2026Open Access
A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity
Figshare·2026Open Access
A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity
2025Open Access
Abstract 2386: Label free imaging for rapid assessment of tumor viability in live tumor fragments
Cancer Research·2023
Abstract 1022: Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2)
Cancer Research·2014· 3 cited
Abstract 2991: Triple combination of bevacizumab, anti-DLL4 (delta like ligand 4) and trebananib gives enhanced therapeutic effects in three xenograft tumor models
Cancer Research·2014
The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma
Translational Oncology·2014· 41 citedOpen Access
Abstract 1608: Angiopoietin 2 is elevated in patients with RCC, and Ang2 inhibition improves antiantiogenic activity of sunitinib in a mouse model of RCC.
Cancer Research·2013
Chromatin, TAFs, and a novel multiprotein coactivator are required for synergistic activation by Sp1 and SREBP-1a in vitro
Genes & Development·1998· 194 citedOpen Access
SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein.
Genes & Development·1996· 153 citedOpen Access
Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues.
PubMed·1995· 590 cited
Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.
Proceedings of the National Academy of Sciences·1994· 278 citedOpen Access
p53 Mutation and MDM2 amplification in human soft tissue sarcomas.
PubMed·1993· 538 cited
Scrambled exons
Cell·1991· 890 cited

Frequent Co-authors

Pichet Adstamongkonkul(8), Christina M. Scribano(8), Christin Johnson(8), Laura Hrycyniak(8), Nicholas Dana(8), Evan Flietner(8), Nicholas Kaplewski(8), Michael Korrer(8), Nathan Marhefke(8), James W. Richardson(8), Pooja Advani(8), Barbara Broome(8), Mercedes Robaina(8), Kevin W. Eliceiri(8), Christian M. Capitini(8), Hinco J. Gierman(8), Christian Baltes(7), Payton McDonnell(7), Ellen E. Wargowski(7), Yanyan Lou(7)